Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on November 13, 2020. The filing primarily addresses executive leadership transitions within the Research and Development and Finance functions, alongside the appointment of a new Chief Medical Officer and the engagement of consultants to support the integration of the US WorldMeds acquisition.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes and Personnel Actions
- Departure of CMO: Stefan K.F. Schwabe, M.D., Ph.D., Executive Vice President of Research and Development and Chief Medical Officer, notified the Company of his retirement effective December 31, 2020.
- Appointment of New CMO: Jonathan Rubin, M.D., was appointed Senior Vice President and Chief Medical Officer, effective January 1, 2021. Dr. Rubin previously served as Senior Vice President, Clinical Research and Medical Affairs at Supernus since February 2020.
- Consulting Engagements:
- Gregory S. Patrick: Entered a consulting agreement effective November 18, 2020, to assist with Finance, Accounting, and US WorldMeds integration. He will receive three monthly payments of $53,333, followed by an hourly rate of $300 through May 18, 2021.
- Stefan K.F. Schwabe: Entered a consulting agreement effective December 31, 2020, to assist with R&D and US WorldMeds integration. He will receive monthly payments of $48,000 through March 31, 2021.
Compensation and Retention Details
Dr. Rubin's compensation package includes:
- Base Salary: $385,000 annually.
- Bonus: Eligible for an annual target bonus of up to 35% of base salary.
- Retention Agreement: Effective January 1, 2021. Provides 12 months of base salary and health benefits upon termination without cause or for good reason. In the event of a change in control, the agreement includes a lump-sum payment equal to the most recent annual bonus and full vesting of stock-based compensation.
Investor Verification Checklist
- Verify the effective dates of Dr. Schwabe's retirement and Dr. Rubin's appointment to ensure continuity in clinical strategy.
- Review the specific terms of the US WorldMeds acquisition integration, as both new consultants are tasked with this function.
- Confirm the impact of the Executive Retention Agreement on potential future change-in-control scenarios.
- Note that the filing text does not provide updated financial guidance or operational metrics for the period.